How Much Does Retatrutide Cost in Colorado in 2026?

Colorado Retail Pricing for Brand-Name Retatrutide

The average cash-pay price for brand-name retatrutide at Colorado retail pharmacies falls between $1,050 and $1,100 per month in 2026. This price reflects the manufacturer's wholesale acquisition cost set by Eli Lilly plus standard pharmacy dispensing margins.

Pricing varies by 10 to 15% across the state depending on pharmacy location and purchasing agreements. Denver metro pharmacies (King Soopers, Walgreens, CVS) tend to cluster near the $1,050 mark, while independent pharmacies in mountain communities or rural eastern Colorado may charge slightly more due to lower purchasing volume. GoodRx and similar discount platforms can reduce the uninsured price to approximately $900, $975 in some locations, though availability of these coupons fluctuates monthly.

Retatrutide is a triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. In the phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine, participants receiving the highest dose (12 mg) achieved 24.2% mean body weight reduction at 48 weeks [1]. This positions retatrutide as one of the most potent weight-loss medications available, which partly explains Eli Lilly's premium pricing strategy.

Eli Lilly Savings Card: How It Works in Colorado

Eligible commercially insured patients in Colorado can reduce their monthly cost to $25 through the Eli Lilly retatrutide savings card program. The card covers the difference between the patient's copay or coinsurance and $25, up to a maximum annual benefit.

Eligibility requires commercial insurance (not Medicare, Medicaid, or Tricare), a valid prescription, and U.S. residency. Colorado patients activate the card through the Lilly website or by calling the number on the card packaging. The card applies automatically at participating pharmacies once linked to the patient's prescription profile.

Patients without any insurance do not qualify for the copay card but may qualify for the Lilly Patient Assistance Program, which provides the medication at no cost to households earning below 400% of the federal poverty level. For a single-person household in Colorado in 2026, that threshold is approximately $62,400 annually. The application requires income verification and prescriber attestation.

One limitation: the savings card has an annual cap (typically $150 per fill, translating to $1,800 per year in savings). Once that cap is reached, patients revert to their plan's standard cost-sharing. Patients starting mid-year should calculate whether the annual benefit will cover their remaining months.

Colorado Medicaid Coverage for Retatrutide

Colorado Medicaid (Health First Colorado) does not cover retatrutide for chronic weight management as of 2026. Coverage is limited to the type 2 diabetes indication only.

This mirrors the Centers for Medicare and Medicaid Services approach that excludes anti-obesity medications from mandatory Medicaid drug coverage under Social Security Act Section 1927(d)(2). Colorado has not opted into voluntary coverage for weight-management indications, unlike a handful of states that have expanded formulary access.

For Colorado Medicaid enrollees with type 2 diabetes and a BMI of 27 or higher, retatrutide may be accessible through prior authorization. The PA process requires documentation of:

• HbA1c ≥ 7.0% despite metformin therapy (or metformin contraindication)
• BMI ≥ 27 kg/m²
• Trial and failure of at least one preferred GLP-1 receptor agonist

Dr. Robert Kushner, professor of medicine at Northwestern University, noted in the Endocrine Society's 2024 clinical practice guideline: "Anti-obesity medications should be considered as adjuncts to lifestyle intervention for patients with BMI ≥ 30, or ≥ 27 with weight-related complications, when lifestyle intervention alone has been insufficient."

Colorado enrollees denied coverage can file a grievance through Health First Colorado's appeals process. The denial letter includes specific instructions, and patients have 60 days from the date of notice to submit their appeal.

Compounded Retatrutide in Colorado: Legality and Pricing

Compounded retatrutide is available through licensed 503A pharmacies in Colorado. State law permits patient-specific compounding when a prescriber writes an individual prescription, and the pharmacy holds a valid Colorado State Board of Pharmacy license.

Monthly pricing for compounded retatrutide in Colorado ranges from $300 to $500, depending on the compounding pharmacy, dose, and concentration. This represents a 55 to 70% discount compared to the brand-name product. Compounding pharmacies source retatrutide active pharmaceutical ingredient (API) from registered suppliers and compound it into subcutaneous injection vials or pre-filled syringes.

Key legal requirements for compounded retatrutide in Colorado:

• The pharmacy must hold a Colorado 503A compounding license
• Each prescription must be patient-specific (no batch distribution without individual Rx)
• The prescriber must have a valid patient-prescriber relationship
• The compound cannot be a copy of a commercially available product in the same strength and dosage form unless a clinical difference is documented

The FDA's guidance on 503A compounding permits compounding of drugs when certain conditions are met, including that the compounding is performed by a licensed pharmacist or physician in response to a valid prescription. Colorado's Board of Pharmacy follows these federal guidelines while adding state-level oversight including annual inspections and potency testing requirements.

Patients considering compounded retatrutide should verify that their pharmacy provides certificates of analysis (COA) for each batch, confirming potency within 90 to 110% of labeled concentration and sterility testing results. Not all compounding pharmacies voluntarily share COAs, so asking directly is appropriate.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for retatrutide in Colorado varies substantially by carrier and plan tier. The three largest carriers in the state (Anthem Blue Cross Blue Shield, UnitedHealthcare, and Kaiser Permanente Colorado) each maintain different formulary positions.

Anthem BCBS Colorado added retatrutide to its preferred specialty tier for type 2 diabetes in 2025 and expanded coverage to chronic weight management for select large-group employer plans in early 2026. Prior authorization requirements include documented BMI ≥ 30 (or ≥ 27 with at least one weight-related comorbidity) and completion of a structured lifestyle program.

UnitedHealthcare plans sold through the Colorado exchange (Connect for Health Colorado) generally cover retatrutide for T2D but require step therapy through semaglutide or tirzepatide before authorizing retatrutide for weight management. This step-therapy requirement adds 3 to 6 months to the access timeline for patients who have not previously tried these medications.

Kaiser Permanente Colorado covers retatrutide through its integrated pharmacy with a specialty copay tier. Members typically pay $75, $150 per month after the savings card is applied, depending on their specific plan design.

For self-funded employer plans administered in Colorado, coverage decisions rest with the employer. Approximately 40% of large Colorado employers (500+ employees) now include at least one GLP-1 or multi-receptor agonist in their pharmacy benefit, according to the Colorado Division of Insurance 2025 market survey.

Telehealth Access to Retatrutide in Colorado

Colorado law permits telehealth prescribing of retatrutide statewide, including initial consultations without a prior in-person visit. The Colorado Medical Board's telehealth rules, updated in 2024, allow prescribers to establish a patient-prescriber relationship via synchronous audio-video communication.

Several telehealth platforms operating in Colorado prescribe retatrutide, with consultation fees ranging from $99 to $199 for the initial visit and $49 to $99 for monthly follow-ups. These fees are separate from the medication cost itself.

Telehealth prescriptions for retatrutide in Colorado can be filled at:

• Any licensed Colorado retail pharmacy (brand product)
• Licensed 503A compounding pharmacies (compounded product)
• Mail-order pharmacies licensed to ship into Colorado

The Jastreboff et al. phase 2 data showed dose-dependent weight loss across all retatrutide arms, with the 12 mg dose producing 24.2% mean weight loss versus 2.1% with placebo at 48 weeks [1]. Telehealth providers typically start patients at 0.5 mg weekly and titrate upward every four weeks following the clinical trial protocol.

Patients in rural Colorado communities (the Eastern Plains, San Luis Valley, and Western Slope) particularly benefit from telehealth access, as endocrinology and obesity medicine specialists concentrate in the Front Range corridor.

Cost Comparison: Retatrutide vs. Other GLP-1 Medications in Colorado

Retatrutide's pricing in Colorado sits within the same range as other incretin-based therapies, though its triple-agonist mechanism offers potentially greater efficacy per dollar spent.

Monthly cost comparison (Colorado cash-pay, no insurance):

• Retatrutide (brand): $1,050, $1,100
• Tirzepatide (Zepbound): $1,000, $1,060
• Semaglutide 2.4 mg (Wegovy): $1,300, $1,400
• Liraglutide 3.0 mg (Saxenda): $1,200, $1,350

The STEP-1 trial (N=1,961) demonstrated semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [2]. Retatrutide's phase 2 data showed 24.2% at 48 weeks, though head-to-head trials are needed for direct comparison. The TRIUMPH phase 3 program is expected to provide definitive efficacy and safety data.

Dr. Ania Jastreboff, associate professor at Yale School of Medicine, stated regarding the phase 2 results: "The magnitude of weight reduction observed with retatrutide, particularly at the higher doses, exceeded what we have previously seen with approved anti-obesity medications in clinical trials" [1].

From a cost-effectiveness standpoint, if retatrutide delivers 60% greater weight loss than semaglutide at a 20% lower monthly price, the cost per percentage point of body weight lost favors retatrutide significantly. Colorado patients considering which medication to pursue should discuss both efficacy expectations and total annual cost with their prescriber.

How to Reduce Your Retatrutide Costs in Colorado

Several strategies can lower out-of-pocket retatrutide expenses for Colorado residents.

Eli Lilly Savings Card. The most direct path for commercially insured patients. Reduces cost to $25/month for eligible patients. Activate online before your first fill.

Compounded alternatives. Licensed 503A pharmacies in Colorado offer retatrutide at $300, $500/month. Verify pharmacy licensure through the Colorado DORA pharmacy lookup database.

Employer advocacy. If your employer's plan excludes weight-management medications, request a formulary exception through HR. Provide clinical documentation of weight-related comorbidities and prior treatment attempts.

Patient assistance programs. Lilly's PAP covers uninsured patients below 400% FPL. Apply directly through the manufacturer with prescriber support.

Dose optimization. Some patients achieve target weight at maintenance doses lower than the maximum 12 mg. Lower doses cost less at compounding pharmacies where pricing is dose-dependent. The phase 2 trial showed the 8 mg dose produced 22.8% weight loss at 48 weeks [1], only 1.4 percentage points less than 12 mg.

HSA/FSA funds. Retatrutide prescribed for any FDA-approved indication qualifies as an eligible medical expense under IRS rules for health savings accounts and flexible spending arrangements.

Safety Considerations and Monitoring Costs

Beyond the medication itself, Colorado patients should budget for associated monitoring costs. Standard follow-up for retatrutide includes quarterly labs and periodic office visits.

Typical monitoring schedule and costs (Colorado averages, uninsured):

• Initial labs (CMP, lipid panel, HbA1c, thyroid function): $150, $250
• Quarterly follow-up labs: $75, $150 per visit
• Office visits (if not using telehealth): $150, $300 per visit
• Annual total monitoring cost: $600, $1,200

The most common adverse events reported in the Jastreboff et al. phase 2 trial were gastrointestinal: nausea (25 to 45% depending on dose), diarrhea (15 to 25%), vomiting (10 to 20%), and decreased appetite [1]. These events were predominantly mild to moderate and occurred primarily during dose escalation. Slow titration (4-week intervals between dose increases) reduced GI side effect severity in the trial protocol.

The glucagon receptor agonism unique to retatrutide raises theoretical concerns about hepatic glucose output. However, phase 2 data showed improved glycemic control across all doses, with HbA1c reductions of 0.4 to 0.5% even in participants without diabetes [1]. Monitoring fasting glucose and HbA1c remains standard practice.

Retatrutide carries the same class-wide boxed warning regarding medullary thyroid carcinoma (MTC) risk observed in rodent studies with GLP-1 receptor agonists. It is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Colorado prescribers should document thyroid history before initiating therapy.